<DOC>
	<DOCNO>NCT02524717</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics JNJ-56021927 participant mild moderate hepatic impairment .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics JNJ-56021927 Participants With Mild Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-dose , single-center , non-randomized study JNJ-56021927 participant either hepatic impairment qualify control group . The study consist 3 Phases : Screening Phase ( 21 Days ) , open-label treatment Phase ( 8 Days ) follow Phase ( 49 Days ) . The duration participation study participant approximately 78 Days . Primarily pharmacokinetics JNJ-56021927 measure . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Must clinically stable hepatic function confirm serum bilirubin transaminase level measure Screening measure within 24 hour prior study drug administration Sign inform consent document indicate participant understands purpose procedure require study willing participate study . Participants must hepatic encephalopathy great equal ( &gt; = ) Grade 3 participant lack capacity provide inform consent judge investigator . Mild moderate hepatic encephalopathy would impede informed consent investigator 's judgment permit Willing able adhere prohibition restriction specify protocol If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate Investigator , always use condom sexual intercourse , agree donate sperm study 3 month receive study drug Body mass index ( BMI ) 18 35 kilogram ( kg ) /meter ( ) ^2 ( inclusive ) , body weight less 50 kg The participant must total ChildPugh score 5 6 , inclusive ( mild ) ; 7 9 , inclusive ( moderate ) ; investigator determine hepatic impairment Screening thyroidstimulating hormone ( TSH ) level great ( &gt; ) Upper Limit Normal ( ULN ) , participant know history thyroid disorder Participant thyroid replacement therapy History drug abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 2 year Screening positive test result ( ) drug abuse ( , opiates , barbiturate , benzodiazepine , cocaine , cannabinoids , amphetamine ) Screening Day 1 . A positive test participant prescription drug may interfere drug screen ( , opiates benzodiazepine ) may allow Known allergy study drug excipients formulation Intention donate blood blood product study 3 month administration study drug A man plan father child enrol study 3 month receive study drug Known history seizure condition may predispose seizure medication lower seizure threshold History stomach intestinal surgery resection would potentially alter absorption excretion orally administer drug Gall bladder ( example , cholecystitis cholelithiasis ) biliary tract disease Clinically significant renal laboratory finding include serum creatinine level great ( &gt; ) 1.5 time ULN Inability fast 12 hour History current clinically significant medical illness Positive test human immunodeficiency virus ( HIV ) 1 2 antibody</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>JNJ-56021927</keyword>
</DOC>